How are the EV-303, EV-304, and VOLGA trials reshaping the treatment landscape for muscle-invasive bladder cancer?
In this EMUC TV interview, our UROONCO BCa chief editor Dr. Benjamin Pradere speaks with Prof. Thomas Powles about the latest evidence from the EV-303, EV-304, and VOLGA trials. Learn how perioperative enfortumab vedotin-based strategies are improving outcomes for patients with muscle-invasive bladder cancer and what these findings may mean for treatment duration, ctDNA-guided decision-making, and the future role of surgery.